These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12215888)

  • 21. Transforming growth factor beta in experimentally detached retina and periretinal membranes.
    Guérin CJ; Hu L; Scicli G; Scicli AG
    Exp Eye Res; 2001 Dec; 73(6):753-64. PubMed ID: 11846507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy.
    Turgut B; Uyar F; Ustundag B; Celiker U; Akpolat N; Demir T
    Retina; 2012 Feb; 32(2):232-41. PubMed ID: 21934553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferation: a key step in the progression of proliferative vitreoretinopathy.
    Zhang L; Li X; Zhao M; He P; Yu W; Dong J; Liu G; Li C; Shi X
    Exp Eye Res; 2006 Dec; 83(6):1405-11. PubMed ID: 16973160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
    Mandava N; Blackburn P; Paul DB; Wilson MW; Read SB; Alspaugh E; Tritz R; Barber JR; Robbins JM; Kruse CA
    Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new model of proliferative vitreoretinopathy.
    Frenzel EM; Neely KA; Walsh AW; Cameron JD; Gregerson DS
    Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2157-64. PubMed ID: 9761295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
    Berger AS; Cheng CK; Pearson PA; Ashton P; Crooks PA; Cynkowski T; Cynkowska G; Jaffe GJ
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2318-25. PubMed ID: 8843916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of TGF-beta and TGF-beta neutralizing antibodies on fibroblast-induced collagen gel contraction: implications for proliferative vitreoretinopathy.
    Pena RA; Jerdan JA; Glaser BM
    Invest Ophthalmol Vis Sci; 1994 May; 35(6):2804-8. PubMed ID: 8188474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy.
    Tahara YR; Sakamoto TR; Oshima YR; Ishibashi TR; Inomata HR; Murata TR; Hinton DR; Ryan SJ
    Curr Eye Res; 1999 Oct; 19(4):323-9. PubMed ID: 10520228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baculovirus is an efficient vector for the transduction of the eye: comparison of baculovirus- and adenovirus-mediated intravitreal vascular endothelial growth factor D gene transfer in the rabbit eye.
    Kinnunen K; Kalesnykas G; Mähönen AJ; Laidinen S; Holma L; Heikura T; Airenne K; Uusitalo H; Ylä-Herttuala S
    J Gene Med; 2009 May; 11(5):382-9. PubMed ID: 19263462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer.
    Kinnunen K; Korpisalo P; Rissanen TT; Heikura T; Viita H; Uusitalo H; Ylä-Herttuala S
    Acta Physiol (Oxf); 2006 Aug; 187(4):447-57. PubMed ID: 16866776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of experimental proliferative vitreoretinopathy by retroviral vector-mediated transfer of suicide gene. Can proliferative vitreoretinopathy be a target of gene therapy?
    Sakamoto T; Kimura H; Scuric Z; Spee C; Gordon EM; Hinton DR; Anderson WF; Ryan SJ
    Ophthalmology; 1995 Oct; 102(10):1417-24. PubMed ID: 9097787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of tranilast on experimental proliferative vitreoretinopathy.
    Ito S; Sakamoto T; Tahara Y; Goto Y; Akazawa K; Ishibashi T; Inomata H
    Graefes Arch Clin Exp Ophthalmol; 1999 Aug; 237(8):691-6. PubMed ID: 10459620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy.
    Shinohara K; Tanaka M; Sakuma T; Kobayashi Y
    Ophthalmic Surg Lasers Imaging; 2003; 34(4):299-305. PubMed ID: 12875458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer.
    Motomura Y; Kanbayashi H; Khan WI; Deng Y; Blennerhassett PA; Margetts PJ; Gauldie J; Egashira K; Collins SM
    Am J Physiol Gastrointest Liver Physiol; 2005 Jan; 288(1):G143-50. PubMed ID: 15297261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-10 in vivo gene expression in a cell-induced animal model of proliferative vitreoretinopathy.
    Bali E; Willermain F; Caspers-Velu L; Dubois C; Dehou MF; Velu T; Libert J; Bruyns C
    Int J Mol Med; 2003 Sep; 12(3):305-10. PubMed ID: 12883645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy.
    Lei H; Hovland P; Velez G; Haran A; Gilbertson D; Hirose T; Kazlauskas A
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2335-42. PubMed ID: 17460299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.
    Ozerdem U; Mach-Hofacre B; Cheng L; Chaidhawangul S; Keefe K; McDermott CD; Bergeron-Lynn G; Appelt K; Freeman WR
    Curr Eye Res; 2000 Jun; 20(6):447-53. PubMed ID: 10980656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of renal glomerular disease using remote delivery of adenoviral-encoded solubletype II TGF-beta receptor fusion molecule.
    Haviv YS; Takayama K; Nagi PA; Tousson A; Cook W; Wang M; Lam JT; Naito S; Lei X; Carey DE; Curiel DT
    J Gene Med; 2003 Oct; 5(10):839-851. PubMed ID: 14533192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Triamcinolone acetonide in the prevention of experimental proliferative vitreoretinopathy].
    Liang HC; Hui YN; Cai YS
    Zhonghua Yan Ke Za Zhi; 1994 Mar; 30(2):122-4. PubMed ID: 8001444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
    Roldán-Pallarés M; Rollín R; Mediero A; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R
    Mol Vis; 2005 Jul; 11():461-71. PubMed ID: 16030497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.